Adamis pharmaceuticals and dmk pharmaceuticals announce agreement and plan of merger

San diego and somerville, n.j., feb. 27, 2023 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, and dmk pharmaceuticals, corp., a private, clinical-stage biotechnology company at the forefront of endorphin-inspired drug design focused on developing novel treatments for opioid use disorder (oud) and other neuro-based diseases, today announced that the companies have entered into an agreement and plan of merger and reorganization (the “agreement”). pursuant to the agreement, adamis will acquire dmk, including its library of approximately 750 small molecule neuropeptide analogues and on-going government funding for its development programs.
ADMP Ratings Summary
ADMP Quant Ranking